Spermatogenic Failure, Nonobstructive, Y-Linked
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
Small testicle
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Real-time quantitative polymerase chain reaction was performed to evaluate the expression of TTTY15-USP9Y and the prostate cancer-specific antigen (PSA) level.
|
26008593 |
2015 |
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
USP9Y-TTTY15 expression is neither higher in cancer than adjacent normal tissues, nor correlated with features of advanced prostate cancer.
|
25188740 |
2014 |
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
USP9Y-TTTY15 expression is neither higher in cancer than adjacent normal tissues, nor correlated with features of advanced prostate cancer.
|
25188740 |
2014 |
Partial chromosome Y deletion
|
0.300 |
ChromosomalRearrangement
|
phenotype |
ORPHANET |
Screening for partial AZFa microdeletions in the Y chromosome of infertile men: is it of clinical relevance?
|
22537385 |
2012 |
Partial chromosome Y deletion
|
0.300 |
ChromosomalRearrangement
|
phenotype |
ORPHANET |
An azoospermic man with a de novo point mutation in the Y-chromosomal gene USP9Y.
|
10581029 |
1999 |
Partial chromosome Y deletion
|
0.300 |
ChromosomalRearrangement
|
phenotype |
ORPHANET |
Genetic dissection of the AZF regions of the human Y chromosome: thriller or filler for male (in)fertility?
|
20671934 |
2010 |
Oligospermia
|
0.130 |
Biomarker
|
disease |
HPO |
|
|
|
Oligospermia
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
Deletions in the azoospermia factor region AZFa on the human Y chromosome and, more specifically, in the region that encompasses the ubiquitin-specific peptidase 9, Y-linked gene USP9Y have been implicated in infertility associated with oligospermia and azoospermia.
|
19246359 |
2009 |
Oligospermia
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
While deletions or even smaller mutations in USP9Y seem to be associated with a testicular phenotype of severe hypospermatogenesis, patients with deletions of DBY may present both Sertoli cell-only syndrome and severe hypospermatogenesis.
|
11097428 |
2000 |
Oligospermia
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
One of these two patients had DFFRY deletion and the other had DBY deletion; their testicular phenotypes were Sertoli cell-only syndrome and hypospermatogenesis, respectively.
|
11695273 |
2001 |
Non-obstructive azoospermia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
We tested transcripts of 14 Y chromosomal genes by RT-PCR (TSPY, DAZ, BPY1 and BPY2, PRY, XKRY, CDY1 and CDY2, TTY1 and TTY2, PRKY, RBMY1, DBY and USP9Y), and only transcript of TSPY was detectable in the tumor tissue.
|
16784771 |
2006 |
Neoplasm, Residual
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
To investigate lineage-specific chimerism of plasma cells after allogeneic transplantation by real-time PCR based on bi-allelic sequence polymorphism or, in case of female-to-male transplantation, on the detection of the DFFRY gene and to determine its value to quantify minimal residual disease in myeloma patients.
|
16647575 |
2006 |
Multiple Myeloma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To investigate lineage-specific chimerism of plasma cells after allogeneic transplantation by real-time PCR based on bi-allelic sequence polymorphism or, in case of female-to-male transplantation, on the detection of the DFFRY gene and to determine its value to quantify minimal residual disease in myeloma patients.
|
16647575 |
2006 |
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
USP9Y-TTTY15 expression is neither higher in cancer than adjacent normal tissues, nor correlated with features of advanced prostate cancer.
|
25188740 |
2014 |
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
USP9Y-TTTY15 expression is neither higher in cancer than adjacent normal tissues, nor correlated with features of advanced prostate cancer.
|
25188740 |
2014 |
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Real-time quantitative polymerase chain reaction was performed to evaluate the expression of TTTY15-USP9Y and the prostate cancer-specific antigen (PSA) level.
|
26008593 |
2015 |
Male sterility due to Y-chromosome deletions
|
0.300 |
ChromosomalRearrangement
|
phenotype |
ORPHANET |
Screening for partial AZFa microdeletions in the Y chromosome of infertile men: is it of clinical relevance?
|
22537385 |
2012 |
Male sterility due to Y-chromosome deletions
|
0.300 |
ChromosomalRearrangement
|
phenotype |
ORPHANET |
Genetic dissection of the AZF regions of the human Y chromosome: thriller or filler for male (in)fertility?
|
20671934 |
2010 |
Male sterility due to Y-chromosome deletions
|
0.300 |
ChromosomalRearrangement
|
phenotype |
ORPHANET |
An azoospermic man with a de novo point mutation in the Y-chromosomal gene USP9Y.
|
10581029 |
1999 |
Male infertility
|
0.140 |
GeneticVariation
|
phenotype |
BEFREE |
Deletions in these regions remove one or more of the candidate genes (DAZ, RBMY, USP9Y, and DBY) and cause severe testiculopathy leading to male infertility.
|
11294825 |
2001 |
Male infertility
|
0.140 |
Biomarker
|
phenotype |
HPO |
|
|
|
Male infertility
|
0.140 |
Biomarker
|
phenotype |
LHGDN |
[A genetic study on microdeletion of azoospermia factor region on Y chromosome of azoospermia and oligozoospermia patients].
|
15696490 |
2005 |